Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Collaborates with RemeGen to Test PD-1/ADC Combination for Solid Tumors

publication date: Jun 26, 2023

Suzhou Innovent Biologics formed a clinical collaboration with RemeGen that will test its PD-1 inhibitor with one of two RemeGen (SHA: 688331; HK: 09995) ADC assets for advanced solid tumors. Innovent will contribute TYVYT® (sintilimab injection), which has been approved in China for seven oncology indications. RemeGen will add either RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC. RemeGen will be responsible for conducting Phase I/IIa clinical studies to assess the anti-tumor activity and safety of the combination. More details....

Stock Symbols: (HK: 01801) (SHA: 688331; HK: 09995)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital